Screening for Anxiety and Depression in people with psoriasis: a cross sectional study in a tertiary referral setting: A cross-sectional study in a tertiary referral setting

TY - JOUR

T1 - Screening for Anxiety and Depression in people with psoriasis: a cross sectional study in a tertiary referral setting

T2 - A cross-sectional study in a tertiary referral setting

AU - Lamb, R.C.

AU - Matcham, Faith

AU - Turner, M

AU - Rayner, L

AU - Simpson, A

AU - Hotopf, M

AU - Barker, J.N.W.N.

AU - Jackson, K

AU - Smith, C.H.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - BACKGROUND National Institute for Health and Care Excellence (NICE) guidance recommends assessment of psychological and social well-being in people with psoriasis. OBJECTIVES To systematically screen for depression and anxiety in patients with psoriasis in routine clinical practice and identify at-risk groups for psychiatric morbidity. METHODS Consecutive patients attending a single, tertiary centre over a 10-month period were invited to complete Patient Health Questionnaire Depression Scale (PHQ-9), Generalized Anxiety Disorder Scale (GAD-7) and Dermatology Life Quality Index (DLQI) as part of the IMPARTS: Integrating Mental and Physical healthcare; Research, Training and Services. Information on demographics, treatment and clinical disease severity were collated from EPR. Regression models were used to identify at-risk groups for psychiatric morbidity. RESULTS Of 607 patients (56.2% on biologics) included, 9.9% (95%CI: 7.5-12.3%) screened positive for major depressive disorder and 13.1% (95%CI: 10.4-15.8%) for generalised anxiety disorder ([GAD] GAD-7 >9). Suicidal ideation was reported in 35% of MDD; DLQI was

AB - BACKGROUND National Institute for Health and Care Excellence (NICE) guidance recommends assessment of psychological and social well-being in people with psoriasis. OBJECTIVES To systematically screen for depression and anxiety in patients with psoriasis in routine clinical practice and identify at-risk groups for psychiatric morbidity. METHODS Consecutive patients attending a single, tertiary centre over a 10-month period were invited to complete Patient Health Questionnaire Depression Scale (PHQ-9), Generalized Anxiety Disorder Scale (GAD-7) and Dermatology Life Quality Index (DLQI) as part of the IMPARTS: Integrating Mental and Physical healthcare; Research, Training and Services. Information on demographics, treatment and clinical disease severity were collated from EPR. Regression models were used to identify at-risk groups for psychiatric morbidity. RESULTS Of 607 patients (56.2% on biologics) included, 9.9% (95%CI: 7.5-12.3%) screened positive for major depressive disorder and 13.1% (95%CI: 10.4-15.8%) for generalised anxiety disorder ([GAD] GAD-7 >9). Suicidal ideation was reported in 35% of MDD; DLQI was

UR - http://www.scopus.com/inward/record.url?scp=84989945712&partnerID=8YFLogxK

U2 - 10.1111/bjd.14833

DO - 10.1111/bjd.14833

M3 - Article

C2 - 27363600

AN - SCOPUS:84989945712

SN - 0007-0963

JO - British Journal of Dermatology

JF - British Journal of Dermatology

ER -